Brief: UCB FY Revenue EUR 6,150 Million Vs. IBES Estimate EUR 5,807 Million
27/02/2025 06:01
Feb 27 (Reuters) - UCB FY adjusted EPS EUR 4.98. outlook FY adjusted EPS EUR 6.8-7.4
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside